TABLE 1.
Patient's characteristics
| MGRS‐A | MGRS‐NA | p‐value | |
|---|---|---|---|
| Number of patients | 180 | 100 | |
| Median age (range), years | 61 (28–87) | 60 (25–87) | 0.2790 |
| Male sex, n (%) | 90 (50.0%) | 51 (49.0%) | 0.8728 |
| Monoclonal component | |||
| Heavy chains, n (%) | <0.0001 | ||
| IgA κ/ λ | 1/9 (5.8%) | 3/3 (6.2%) | |
| IgG κ/ λ | 10/41 (29.7%) | 39/16 (56.7%) | |
| IgM κ/ λ | 4/8 (7.0%) | 5/1 (6.2%) | |
| Free light chains | |||
| κ | 24 (14.0%) | 23 (23.7%) | |
| λ | 75 (43.6%%) | 7 (7.2%) | |
| Type of MGRS | |||
| MIDD | Not applicable | 53 (53%) | ‐ |
| PGNMID | 14 (14%) | ||
| LCPT | 11 (11%) | ||
| Monoclonal fibrillary GN | 4 (4%) | ||
| Immunotactoid GN | 4 (4%) | ||
| C3 glomerulopathy with monoclonal gammopathy | 7 (7%) | ||
| Other | 5 (5%) | ||
| Cryoglobulinemic GN | 2 (2%) | ||
| Laboratory parameters, median (range) | |||
| Bone marrow involvement (% PCs), median* (range) | 5.7% (0–50) | 7.5% (0–55) | 0.1386 |
| Monoclonal component (mg/dL), median* (range) | 5.0 (0–3000) | 57 (0–2460) | 0.0763 |
| FLC κ, median (range) (mg/dL), median* (range) | 21.1 (0–2152) | 71.4 (1.4–6680) | <0.0001 |
| FLC λ, (mg/dL), median* (range) | 21.8 (0–4260) | 68.6 (0–1815) | <0.0001 |
| FLC κ/λ, median* (range) | 0.4 (0–309) | 3.5 (0–1040) | < 0.0001 |
| Albumin (≥3.5 mg/dL), n (%) | 153 (93.3%) | 85 (92.4%) | 0.7871 |
| B‐2‐microglobulin (≥5.5 mg/L), n (%) | 26 (34.2%) | 34 (54.8%) | 0.0055 |
| LDH ≥300 U/L, n (%) | 46 (36.8%) | 22 (26.5%) | 0.1221 |
| Creatinine ≥177 mg/dL, n (%) | 51 (32.3%) | 58 (58.0%) | <0.0001 |
| eGFR <60 ml/min/1.73m2, n (%) | 97 (54.5%) | 72 (88.8%) | <0.0001 |
| 24 h urine protein (g) | 6.2 (0.1–14 850) | 3.4 (0–7000) | 0.0001 |
| Dialysis, n (%) | 33 (18.3%) | 26 (26.0%) | 0.0004 |
| Treatment, n (%) | |||
| Untreated | 25 (13.9%) | 12 (12.0%) | 0.0614 |
| 1 line | 106 (58.9%) | 65 (65.0%) | |
| 2 lines | 35 (19.4%) | 17 (17.0%) | |
| 3 lines | 14 (7.8%) | 6 (6.0%) | |
Abbreviations: eGFR, estimated glomerular filtration rate; FLC, free light chains; GN, glomerulonephritis; LCPT, light chain proximal tubulopathy; LDH, lactate dehydrogenase; MGRS‐A, amyloidoid‐associated monoclonal gammaglobulinemia of renal significance; MGRS‐NA, non‐amyloidosis‐associated gammaglobulinemia of renal significance; MIDD, monoclonal immunoglobulin deposition disease; PGNMID, proliferative glomerulonephritis with monoclonal immunoglobulin deposition disease monoclonal fibrillary glomerulonephritis.
*
Values based on the nonmissing data.